Introduction
New Zealand’s healthcare system is increasingly adopting connected medical technologies such as insulin pumps and Continuous Glucose Monitoring (CGM) systems to improve diabetes care. These devices enable real-time monitoring, automated insulin delivery, and enhanced patient outcomes. However, their integration with mobile applications, wireless communication protocols, and cloud platforms significantly expands the cybersecurity attack surface.
Insulin pump and CGM ecosystems are no longer isolated devices—they function as interconnected digital health systems. This connectivity introduces risks such as unauthorized access, data manipulation, and remote control of device functions. Regulatory authorities have already identified cybersecurity vulnerabilities in insulin pump systems, where attackers could potentially interfere with insulin delivery through compromised communication channels.
To address these risks, manufacturers and healthcare organizations in New Zealand must implement robust security testing aligned with global frameworks such as EU MDR and FDA 510(k). Cyberintelsys enables organizations to secure their medical device ecosystems while ensuring regulatory compliance and patient safety.
Regulatory Alignment for Medical Device Cybersecurity
Medical device cybersecurity is a critical requirement for global market access. For insulin pump and CGM ecosystems, compliance extends beyond safety and performance to include comprehensive cybersecurity validation.
EU MDR emphasizes secure product design, lifecycle risk management, and continuous monitoring. It introduces stricter requirements for cybersecurity, making it a core component of medical device compliance.
FDA 510(k), based on premarket submission requirements, mandates that manufacturers demonstrate device safety and effectiveness while addressing cybersecurity risks. The FDA highlights the importance of threat modeling, vulnerability management, and secure software development as part of regulatory submissions.
In New Zealand, while local regulatory frameworks are aligned with international standards, manufacturers aiming for global distribution must comply with EU and U.S. requirements. Security testing aligned with EU MDR and FDA 510(k) helps organizations achieve compliance, streamline approvals, and ensure device security.
Importance of Security Assessment for Insulin Pump / CGM Ecosystems
Insulin pump and CGM ecosystems involve multiple interconnected components, including embedded firmware, wireless communication modules, mobile applications, and cloud platforms. Each layer introduces potential vulnerabilities that must be addressed.
A comprehensive security assessment is essential for ensuring safe and reliable device operation.
Key benefits include:
Patient Safety Protection
Prevent unauthorized manipulation of insulin delivery or glucose readings that could lead to critical health risks.Cyber Threat Prevention
Identify and mitigate vulnerabilities in wireless communication, APIs, and cloud systems.Regulatory Compliance Support
Meet EU MDR and FDA 510(k) cybersecurity expectations with validated testing and documentation.Data Privacy and Integrity
Protect sensitive patient data from breaches, leaks, and tampering.End-to-End Ecosystem Security
Ensure all interconnected components function securely without introducing systemic risks.
As connected medical devices continue to evolve, cybersecurity becomes a fundamental requirement for maintaining both patient safety and regulatory approval.
Our Methodology: Medical Device Security Testing Methodology
Cyberintelsys follows a structured, risk-based methodology aligned with EU MDR and FDA 510(k) expectations to secure insulin pump and CGM ecosystems.
1. Asset Identification and System Mapping
All ecosystem components including devices, firmware, communication interfaces, mobile apps, and cloud infrastructure—are identified to establish a complete attack surface.
2. Threat Modeling and Risk Analysis
Potential attack vectors such as wireless exploitation, unauthorized access, and API abuse are analyzed to prioritize high-risk areas.
3. Vulnerability Assessment
Automated tools and manual techniques are used to detect vulnerabilities across embedded systems, applications, and networks.
4. Penetration Testing
Simulated real-world attacks validate the exploitability and impact of identified vulnerabilities.
5. Wireless and Communication Security Testing
Protocols such as Bluetooth and Wi-Fi are tested for secure pairing, encryption, and authentication to prevent unauthorized access.
6. Application and Cloud Security Testing
Mobile applications and backend platforms are assessed for insecure APIs, weak authentication, and data exposure risks.
7. Compliance Mapping and Reporting
Findings are mapped against EU MDR and FDA 510(k) requirements, with detailed reports providing remediation guidance and audit-ready documentation.
This structured methodology ensures comprehensive security validation across the entire medical device ecosystem.
Cyberintelsys Security Testing Services
Cyberintelsys delivers specialized security testing services for insulin pump and CGM ecosystems in New Zealand, ensuring compliance, resilience, and patient safety.
1. Vulnerability Assessment (VA)
Identifies security weaknesses across devices and systems.
Detection of known and emerging vulnerabilities
Risk-based prioritization
Actionable remediation guidance
2. Penetration Testing (PT)
Simulates real-world cyberattacks to validate exploitability.
Black-box and white-box testing
Controlled exploitation techniques
Impact and risk validation
3. Embedded Device Security Testing
Focuses on firmware and hardware security of insulin pumps.
Firmware analysis and reverse engineering
Secure boot validation
Hardware interface testing
4. Wireless Security Testing
Evaluates communication channels within CGM ecosystems.
Bluetooth and Wi-Fi security validation
Encryption and authentication testing
Detection of man-in-the-middle vulnerabilities
5. Mobile Application Security Testing
Assesses companion apps used for monitoring and control.
Authentication and session management testing
Secure data storage and transmission
API vulnerability assessment
6. Cloud and Backend Security Testing
Evaluates cloud infrastructure supporting connected devices.
API security validation
Access control and configuration review
Data protection assessment
7. Compliance-Focused Security Testing
Ensures alignment with EU MDR and FDA 510(k).
Gap analysis against regulatory expectations
Documentation support for submissions
Risk management validation
Why Choose Cyberintelsys
Cyberintelsys is a trusted cybersecurity partner for medical device manufacturers and healthcare organizations in New Zealand.
Regulatory-Focused Approach
Security testing aligned with EU MDR and FDA 510(k) expectationsMedical Device Expertise
Strong understanding of insulin pump and CGM ecosystemsComprehensive Security Coverage
End-to-end testing across devices, applications, networks, and cloudRisk-Based Testing Strategy
Focus on vulnerabilities that impact patient safety and device functionalityActionable Reporting
Clear insights with prioritized remediation steps
Cyberintelsys is a CREST-accredited cybersecurity company for Vulnerability Assessment (VA) and Penetration Testing (PT), delivering industry-recognized security testing services for organizations across multiple sectors.
Contact us
As New Zealand continues to adopt advanced connected healthcare technologies, ensuring the security of insulin pump and CGM ecosystems is critical. Cyber threats targeting medical devices are evolving, making proactive security testing essential for compliance and patient safety.
Cyberintelsys helps organizations identify vulnerabilities, strengthen cybersecurity posture, and achieve compliance with EU MDR and FDA 510(k) requirements through comprehensive testing services.
Connect with Cyberintelsys to secure your insulin pump and CGM ecosystem, meet global regulatory standards, and protect patients in an increasingly connected healthcare landscape.
